Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2022-05-18 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - "DOXOFYLLINE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the drug registration approval of a product called 'Doxofylline Injection'. It is an announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document is short (2238 characters) and does not contain financial data or detailed report content. It is not an AGM material, voting result, or board change notice. It is a regulatory announcement about product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-05-18 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from the company CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the unaudited first quarterly results for the three months ended 31 March 2022. It does not contain the actual financial results or detailed financial data, but rather informs about the upcoming board meeting where such results will be approved. The document length is short (1272 characters) and it is clearly an announcement rather than a report. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement about the board meeting and upcoming financial results approval, not the financial report itself.
2022-05-13 English
VOLUNTARY ANNOUNCEMENT - "DONEPEZIL HYDROCHLORIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the approval of a drug product by the National Medical Products Administration of China. It is a short announcement (2447 characters) and does not contain financial data, financial statements, or detailed report content. It is not an annual or interim report, earnings release, or any detailed regulatory filing. The content focuses on a product approval, which is a corporate announcement rather than a financial or regulatory report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-05-05 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2022
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 April 2022. It details movements in issued shares, share options, and confirms no changes in authorized share capital or other agreements. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share option movements. It does not contain financial statements, earnings data, or management discussion. It is a regulatory filing related to share capital movements and share options, fitting the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Share Issue/Capital Change (SHA) because it is a monthly return report rather than an announcement of a new share issue or capital change event. The document length is about 5,098 characters, which is substantive and not a mere announcement. Therefore, the best classification is Regulatory Filings (RNS).
2022-05-03 English
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2022
Interim / Quarterly Report Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the principal financial information of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the three months ended 31 March 2022. It references the subsidiary's 2022 First Quarterly Report and provides detailed financial data including revenue, net profit, cash flows, and explanations for significant changes in accounting data and financial indicators. The document contains substantive financial data and analysis for a quarterly period, not just a brief announcement or a link to a report. It is not a full annual report but a quarterly financial report with detailed financial statements and explanations. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-28 English
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE FGFR4 INHIBITOR "SYHX2005" OBTAINS CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new drug product. It is a short announcement (2162 characters) and does not contain financial data, regulatory certifications, or detailed financial reports. It is not an annual or interim report, earnings release, or any form of financial filing. It is also not related to shareholder meetings, voting results, or management changes. The content focuses on a product development milestone and regulatory approval, which fits best under a general regulatory or company announcement category. Given the short length and nature of the content, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2022-04-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.